**Sclerotherapy for the primary prevention of bleeding from esophageal varices. A randomized controlled multicentre trial**

Henk R. van Buuren¹, Marijke C. Rasch², Piet L. Batenburg³, Clemens J.M. Bolwerk⁴, Jan J. Nicolai⁵, Sjoerd D.J. van der Werf⁶, Joost Scherpenisse⁷, Lidia R.Arends⁸, Jan van Hattum², Erik A.J. Rauws⁴, Solko W. Schalm¹

¹Departments of Gastroenterology and Hepatology¹ and Epidemiology and Biostatistics⁸, Erasmus MC, University Medical Center Rotterdam
²Department of Gastroenterology and Hepatology, University Hospital Utrecht
³Department of Internal Medicine, Zuiderziekenhuis, Rotterdam
⁴Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam
⁵Department of Gastroenterology and Hepatology, Ziekenhuis Leyenburg, Den Haag
⁶Department of Internal Medicine, Westeinde Hospital, Den Haag
⁷Department of Gastroenterology, Reinier de Graaf Gasthuis, Delft

**Abstract**

**Background**

Since esophageal variceal bleeding is associated with a high mortality rate, prevention of bleeding might be expected to result in improved survival. The first trials to evaluate prophylactic sclerotherapy found a marked beneficial effect of prophylactic treatment. These results, however, were not generally accepted because of methodological aspects and because the reported incidence of bleeding in control subjects was considered unusually high. The objective of this study was to compare endoscopic sclerotherapy (ES) with a medical regimen for the primary prophylaxis of esophageal variceal bleeding in patients with cirrhosis.

**Methods**

166 patients with esophageal varices grade II, III of IV according to Paquet’s classification, with evidence of active or progressive liver disease and without prior variceal bleeding, were randomized to groups receiving ES (n=84) or no specific treatment (n=82). Primary end-points were incidence of bleeding and mortality; secondary end-points were complications and costs.

**Results**

During a mean follow-up of 32 months variceal bleeding occurred in 25% of the patients of the ES group and in 28% of the control group. The incidence of variceal bleeding for the ES and control group was 16% and 16% at 1 year and 33% and 29% at 3 years, respectively. The 1-year survival rate was 87% for the ES group and 84% for the control group; the 3-year survival rate was 62% for each group. In the ES group one death occurred as a direct consequence of variceal bleeding compared to 9 in the other group (p=0.01, log-rank test). Complications were comparable for the two
groups. Health care costs for patients assigned to ES were estimated to be higher. Meta-analysis of a large number of trials showed that the effect of prophylactic sclerotherapy is significantly related to the baseline bleeding risk.

**Conclusion**
In the present trial, prophylactic sclerotherapy did not reduce the incidence of bleeding from varices in patients with liver cirrhosis and a low to moderate bleeding risk. Although sclerotherapy lowered mortality attributable to variceal bleeding, overall survival was not affected. The effect of prophylactic sclerotherapy seems dependent on the underlying bleeding risk. A beneficial effect can only be expected for patients with a high risk for bleeding.

**Background**
About one-third of patients with liver cirrhosis and varices are likely to undergo hemorrhage during their lifetime [1-5]. The average mortality due to the first variceal bleeding has been estimated to be about 30-50% [1, 6, 7]. Variceal bleeding therefore represents a frequent cause of death and one might expect survival to improve if bleeding could be prevented. The potential of primary prevention of variceal bleeding to improve prognosis is dependent on the severity of the underlying disease. There is a close relationship between (risk of) bleeding and degree of liver failure. Often bleeding precipitates or exacerbates liver failure, while deteriorating liver function frequently precedes variceal bleeding. Obviously, prevention of bleeding in end-stage disease is unlikely to affect prognosis. For patients with a relatively preserved liver function, however, prevention of bleeding might improve prognosis, by reducing mortality due to exsanguination as well as from the complications frequently encountered after variceal bleeding, including hepatorenal syndrome, infections and multi-organ failure. The first type of primary prophylaxis evaluated was the portacaval shunt [3-5]. Although shunt surgery reduced the frequency of bleeding, the rate of both mortality and encephalopathy was increased. Data on other prophylactic surgical procedures are limited and do not allow conclusions [8]. The first reports on the use of prophylactic sclerotherapy suggested that this procedure not only significantly reduced the incidence of variceal bleeding [9-12] but also lowered overall mortality [10, 12]. However, the results of these trials were disputed, mainly because the reported bleeding risk for control patients in some studies was considered exceptionally high and treatment of acute variceal bleeding episodes was not the same for the two treatment groups [1, 13]. The aim of the present multicentre study was to evaluate the effect of endoscopic sclerotherapy for the primary prevention of variceal bleeding in an adequate number of patients with cirrhosis and esophageal varices, with uniform treatment of variceal bleeding in both groups.

**Methods**

**Patient selection**
Eligible patients were adults with endoscopically documented grade II, III or IV esophageal varices [14], absence of prior bleeding from varices, evidence of active and/or progressive liver disease (e.g. as indicated by repeatedly elevated serum
transaminases or increasing serum bilirubin levels or development of ascites within the past year) or documented increase in the size of esophageal varices; all patients gave informed consent. Patients were excluded for the following reasons: malignancy, hemophilia, age older than 70-75 years, no opportunity for follow-up visits.

Centers, study design, randomization and informed consent
This was a multicentre randomized controlled trial that started on 1 May 1986. Patients were included until May 1993 and followed until November 1993. Participating centers (number of patients in parentheses) were the University Hospital Rotterdam (coordinating center)(81); the University Hospital Utrecht (25); the Zuiderziekenhuis, Rotterdam (17); the Academic Medical Center, Amsterdam (15); the Ziekenhuis Leyenburg (12) and Westeinde Hospital (10), The Hague; and the Reinier de Graaf Gasthuis, Delft (6). Randomization was performed according to Zelen’s pre-randomization design [15]. After assessment of eligibility, patients were randomized and provided with oral and written information; they were then asked to participate and give informed consent. This procedure was expected to facilitate patient entry, being considered defensible and appropriate taking into account the marked difference between the two treatment options [16]. The medical ethical committee of one center did not approve of the pre-randomization method; in this center the conventional procedure was followed. Treatment was assigned centrally, by telephone contact or by visiting the trial office, using opaque, serially numbered sealed envelopes. Patients were stratified for center and severity of liver disease according to the Child-Pugh classification [17]. Follow-up started at the time of randomization. Patients gave written informed consent. The medical ethical committees of the participating centers approved the trial.

Endoscopic sclerotherapy
Experienced endoscopists performed all procedures using fiber or video-endoscopes. Patients received intravenous sedation consisting of 0.075 – 0.2 mg midazolam/kg. Varices were injected at multiple sites with 0.5-3 ml ethoxysclerol (polidocanol) 1% or 2% (Kreussler, Germany), proceeding upwards from the gastroesophageal junction. The maximum injection volume was 35 ml/session. Patients were hospitalized for the first sclerotherapy session. Successive treatments were planned on an outpatient basis at 3-week intervals until variceal obliteration was achieved. The aim of sclerotherapy was complete variceal eradication. Subsequently control examinations were performed at 6-month intervals. Recurrent varices were treated. When eradication was established on two subsequent visits further control examinations were scheduled at yearly intervals.

Entry and follow-up procedures
Before randomization, all patients underwent upper gastrointestinal endoscopy. Esophageal varices were classified according to Oberhammer and Paquet [14]. Meetings of participants were organized to review and standardize diagnostic aspects. The Child-Pugh classification system [17] was used as a measure of functional hepatic reserve. General care of the patients in both groups was identical and involved clinical and biochemical assessment at 3-month intervals.
Definition of key events; management of rebleeding and complications
We used international consensus definitions of variceal bleeding and variceal rebleeding[18]. For both groups, the standard therapy for variceal bleeding was resuscitation followed by endoscopic sclerotherapy according to the methods described above, but at intervals of one week until variceal obliteration was achieved. Subsequently, follow-up examinations were performed after 3 months, and then at 6, 9 and finally 12-month intervals. Balloon tamponade was performed when variceal bleeding was not controlled by ES for a period of up to 24 hours and was followed by renewed ES. Therapy for patients with persistent or recurrent variceal bleeding was not defined and decisions were left to the discretion of the individual hospital departments. Variceal obliteration was defined as variceal thrombosis and absence of variceal blood flow as assessed by needle puncture. Variceal eradication was defined as visual absence of variceal columns. Procedure-related mortality was defined as death within 30 days of ES. Esophageal mucosal ulcers after ES were not regarded as a complication unless they caused symptoms, including bleeding and pain.

Analysis of costs
An estimation of the direct medical costs was made by comparing the time spent in the intensive care unit and the ordinary ward, the number of visits to the outpatient department and the number of upper gastrointestinal endoscopies, including sclerotherapy procedures. Only patients admitted to the University Hospital Rotterdam were included. Indirect costs, e.g. economic loss due to inability to work, were not taken into consideration.

Statistics
A sample size calculation was performed assuming a 30% and 10% incidence of bleeding 3 years after entry for the control and ES groups, respectively. To detect this difference with a significance level (alpha) of 0.05 and a power of 90%, and using a two-tailed test, we calculated that we needed to recruit 79 patients for each treatment group. Analyses were performed on an intent-to-treat basis. The primary end-points of this study were variceal bleeding and mortality. Secondary end-points were complications and health-care costs.
Bleeding and mortality were analyzed using the Kaplan-Meier method. Differences between groups were compared by means of the log-rank test. The $\chi^2$ test was used to analyze differences between groups for qualitative data. Paired and unpaired t-tests, or their non-parametric equivalents where appropriate, were used for quantitative data. For analyzing the relationship between baseline bleeding risk and the effect of prophylactic sclerotherapy on the risk of a first variceal bleeding, as reported in the literature and including data of the present trial, the method proposed by Arends et al [19] was used. A two-tailed p-value $\leq 0.05$ was considered significant.

Results
Of the 166 patients enrolled in the study 84 were randomized to undergo ES and 82 to the control group (Figure 1). Patient characteristics of the two groups were comparable (table 1). Mean follow-up was $32 \pm SD 25$ (range 0.1 – 88.5) months; for the ES group $30 \pm 23$ months and for controls $34 \pm 27$ months. Follow-up was incomplete for 11 (ES group 7) patients due to removal, emigration or other reasons. For these cases data were censored at the time of the last visit. In all cases, however,
efforts were undertaken to determine whether the patients were alive at the time of analysis and this information, including causes of death, was used for analysis.

**Procedures**

For sixteen patients assigned to undergo ES, treatment was not instituted because of refusal (n=13), concomitant medical problems (n=2) or miscommunication resulting in failure to initiate ES (n=1). ES was offered to one control patient who repeatedly expressed the explicit wish to be treated because of fear of bleeding. No patient refused to participate in the trial with respect to the prospective recording of follow-up data. During follow-up 9 patients of the control group and 4 of the ES group received a liver transplant. For these cases data were censored at the time of transplantation.

**Bleeding**

(Table 2) Both the number of patients and the number of episodes of variceal bleeding in the two groups were comparable. The same applied for bleeding due to non-variceal causes. The incidence of bleeding from varices (Figure 2) for the ES and control groups was 16% and 16% at 1 year, 29% and 29% at 3 years and 33% and 35% at 4 years, respectively (NS). Variceal bleeding occurred in 7 of 16 (43%) patients of the ES group who did not receive therapy. For 10/14 patients of the ES group variceal bleeding occurred early (mean 3.5 months, range 1 day - 9 months), before variceal eradication had been achieved. Two of these patients had a variceal bleeding after randomization but before ES was started. In 4 patients who had ES which resulted in variceal eradication, variceal bleeding occurred after a mean period of 28 months and 5.5 (range 4-9) ES sessions.

The incidence of upper gastrointestinal hemorrhage due to all causes was 22% for the ES group and 25% for the control group after 1 year and 35 and 36 % after 3 years. Per protocol analysis of those patients who underwent the allocated treatment showed that the incidence of variceal hemorrhage for the ES and control group was 17% and 14% after 1 year and 19% and 29% after 3 years, respectively. The 1 and 2 year incidence of upper gastrointestinal hemorrhage due to all causes was 21% and 29% for the ES group and 15% and 36% for the control group, respectively (NS).

**Mortality**

Twenty-nine (35%) patients of the ES group died and 33 (40%) of the control group (Table 3). In the ES group only 1 death occurred as a direct consequence of variceal bleeding compared to 9 in the other group (p=0.01, log-rank test). The frequency of other causes of death was comparable. The 1-year survival rate was 87% for the ES group and 84% for the control group; the 3-year survival rate was 62% for each group (figure 3). Univariate analysis showed that 3-year survival for Child-Pugh classes A, B and C patients was 77%, 45% and 31% (p = 0.05). No relationship was found between mortality and the size of esophageal varices, etiology of liver disease or participating center.
Complications
Clinical events believed to be related to previous sclerotherapy were compared between both treatment groups (Table 4). Although more complications were noted in the ES group, the difference was not significant. One fatal complication occurred in a patient of the ES group due to esophageal perforation after two treatment sessions. Two patients developed symptomatic submucosal esophageal hematomas, and in one case this complication was observed on two occasions. In all cases spontaneous and complete resolution ensued. Two to four endoscopic dilatations were required in 3 cases of esophageal stenosis following sclerotherapy; in all cases the symptoms were alleviated. We found no evidence that the frequency of complications differed between centers. 8/91 (9%) Child-Pugh class A patients suffered a complication compared to 8/57 (14%) class B patients and 1/18 (6%) class C patients (NS). Thus, no clear relationship was found between the risk of complications and the severity of liver disease.

Costs
In the University Hospital Rotterdam, 299 upper gastrointestinal procedures were carried out in 41 patients assigned to receive ES, compared to 89 procedures for the control group (n=40) (p=.0001). The mean number of days in hospital was 55 for the ES and 35 for the control patients (NS). The total number of days in hospital was 2277 for the ES group and 1400 for the control group (p=0.05). The time spent in intensive care (ES group 58, controls 48) was comparable but ES patients spent significantly more time in other wards (2219 vs. 1352 days). The numbers of visits to the outpatient department (ES group: mean 13.4; total 549; control group: mean 12.8; total 512) were comparable. Altogether, these data indicate that ES was the more expensive strategy, suggesting that the initially higher costs of prophylaxis due to hospital admissions and endoscopic procedures were not compensated by potentially decreased medical consumption over time.

Discussion
In this randomized trial primary prevention of variceal bleeding using endoscopic sclerotherapy did not reduce the bleeding risk for patients with liver cirrhosis and esophageal varices. We found that prophylactic sclerotherapy lowered the risk of fatal variceal bleeding without affecting overall survival. Finally, complications and costs were more marked among patients receiving endoscopic prophylaxis. Several factors could possibly explain why sclerotherapy was not found to reduce the risk of variceal bleeding in the current trial. We may have failed to detect a real treatment effect, a type II statistical error. Although the sample size of this study seemed adequate, a type II error remains a realistic possibility, in particular because nearly 20% (16/84) of patients did not undergo the assigned sclerotherapy treatment. Since the bleeding risk for this particular subgroup was high, this may have diluted the beneficial effects of endoscopic prophylaxis. Although per protocol analysis showed a trend in favor of this possibility, it was not significant. Another factor that could have obscured benefits of ES is an unexpected low bleeding rate for the control group. However, we found that the 3-year bleeding risk for control patients was very similar to the predicted 30%, and consequently that this factor does not seem of importance. Although this was a randomized trial, one can never guarantee similarity
between groups as far as prognostic variables are concerned. Moreover, differences between groups in baseline bleeding risk could be a source of bias. The distribution of variables of prognostic significance in the two groups, particularly Child-Pugh scores, age and variceal size, however, make it unlikely that such a bias was important. Sclerotherapy could increase the initial risk of (variceal) bleeding but have a protective effect over time, eventually translating into an overall treatment benefit. We found some evidence to support this possibility since the majority of variceal bleeding episodes were observed before achieving variceal eradication, and bleeding after eradication was a rare event. It has been noted previously that the bleeding risk for patients recruited for trials of prophylactic therapy seems highest during the first months of follow-up and decreases to about 1/3 after one year [1, 3]. This may suggest that, in retrospect, our sclerotherapy protocol was not optimal and a more intensive regimen, resulting in more rapid eradication of varices [20], could have been more effective.

In this trial ES significantly reduced the mortality rate for variceal bleeding, a finding also reported by other groups[10, 20-24]. In only a few studies, however, was this associated with a corresponding improvement in overall survival [10, 20, 21, 24]. In these studies variceal bleeding occurred in at least 50% of control patients and was the main cause of death, accounting for 65-80% of mortality. This suggests that the magnitude of the effect of prophylactic sclerotherapy on the risk for variceal bleeding, but also on mortality, is dependent on the baseline bleeding risk. This hypothesis was supported by D’Amico, who found a clear relationship between the effect of sclerotherapy on the incidence of bleeding and the baseline bleeding risk as reported in a large number of randomized controlled trials [25]. However, the Bayesian statistical method he used [26] was not optimal [19]. For analyzing the relationship between baseline risk and treatment effect we therefore used another approach [19]. We found, in agreement with D’Amico’s results, that a significant (p<0.001) relationship exists between the baseline bleeding risk and the effect of treatment when analyzing the results of trials of prophylactic sclerotherapy (Figure 4 and 5), which cannot be attributed to ‘regression to the mean’. Thus, endoscopic sclerotherapy is likely to reduce bleeding risk, and probably also mortality, only for patients with a particularly high risk of bleeding. Identification of such patients is possible using the NIEC, or comparable, indices [27, 28]. For patients with a low bleeding risk, the effect of sclerotherapy will be marginal or absent; sclerotherapy might even have a deleterious effect. The numerous trials on prophylactic sclerotherapy have been subjected to meta-analysis [29-32]. All studies have produced a statistically significant pooled estimate of treatment effect on bleeding risk and mortality in favor of sclerotherapy. Like the results of the individual studies, the conclusions based upon these analyses have been diverse, varying from an undetermined effect of sclerotherapy [30, 31] to sclerotherapy being effective, particularly for high-risk patients [29, 32]. One meta-analysis [32] yielded a marked difference in the outcome of trials according to the type of sclerosant used, the results clearly favoring polidocanol. The general recommendation emerging from international consensus conferences [18, 33, 34] has been that sclerotherapy should not be used for primary prophylaxis of variceal bleeding, mainly because of the statistically significant heterogeneity of the treatment effects as observed in studies, and the availability of a non-invasive and cheap alternative (non selective β-blocker treatment).

When the trial was designed the possibility existed that, as a result of the pre-randomization method, not all patients would accept the assigned treatment. In
practice, refusal proved to be a more frequent problem than expected, which complicated the interpretation of results. However, this problem is not unique to the pre-randomization method and similar difficulties can occur with conventional randomization [3, 5, 35-37]. Otherwise, no problems were encountered and our general experience was that the method worked well. Unfortunately, our study design did not allow us to assess whether pre-randomization indeed resulted in increased patient recruitment. Pre-randomization has the potential advantage that, at least in theory, all eligible patients will be selected while the conventional method implies that only a selection of eligible patients will be entered. Consequently, the results of trials using this allocation method may have wider applicability.

The observed rate of complications of sclerotherapy in this study is in agreement with previously reported data. In some studies, however, complications were much more frequent [38, 39]. An explanation for these divergent results remains speculative. Variations in technique [32], technical skill and experience with endoscopic sclerotherapy could at least partially account for some of the reported differences. Our estimation of costs was based on a proportion of patients and the results obviously are preliminary in nature. Nevertheless, our data suggest that prophylactic treatment was the more expensive option. Taking into account the other findings, the cost/benefit ratio of prophylactic sclerotherapy as applied in this study seems unfavorable.

Conclusions
The present results does not support the use of sclerotherapy for primary prevention of variceal bleeding when patients are selected according to the criteria we used. Nevertheless, according to cumulative data from a large number of trials, it can be concluded that endoscopic sclerotherapy can result in a significant decrease in the bleeding risk and, probably, also in bleeding-associated mortality, but only in selected cases with a high bleeding risk. On the basis of lower rates of rebleeding, mortality, complications and the need for fewer endoscopic treatments, variceal band ligation has been shown to be superior to sclerotherapy for secondary prophylaxis of variceal bleeding [40]. Several trials have now evaluated band ligation for primary prophylaxis of variceal bleeding. In most, but not all [41], studies band ligation significantly reduced the bleeding risk when compared to control patients [41-43] or administration of propranolol [44], and in one study ligation was also found to improve survival [43]. Additional studies comparing band ligation and non-selective β-blockers are needed before the role of ligation for primary prevention of variceal bleeding can be defined more precisely. For the time being, β-blockers remain the principal option for primary prophylaxis of variceal bleeding. For patients with contraindications or intolerance for β-blockers and for those who are not compliant or do not respond to treatment, variceal band ligation rather than sclerotherapy may be considered for primary prophylaxis [45].

Competing interests
None declared.
Authors' contributions

HB initiated the study and was the principal investigator, coordinator and author. MR, PB, CB, JN, SW, JS, JH and ER were all involved in the design and the execution of the study. LA performed the statistical meta-analyses. SW conceived of the study and participated in its design and coordination. All authors read and approved of the final manuscript.

Acknowledgements

We are indebted to Margriet Leeuwesteijn for secretarial assistance. Supported by grant OG 90/006 from the Ziekenfondsraad.

References

28. C Merkel, M Zoli, S Sirino, HR van Buuren, D Magalotti, P Angeli, D Sacerdoti, L Bolondi, A Gatta: Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to


**Figures**

**Figure 1**  
Trial profile.

**Figure 2**  
Kaplan-Meier plot showing the percentage of patients free of variceal bleeding (S: sclerotherapy group; C: control group).

**Figure 3**  
Kaplan-Meier plot showing the percentage of surviving patients (S: sclerotherapy group; C: control group). Overall survival (black lines) was comparable. Mortality due to variceal bleeding (dotted lines) in the sclerotherapy group was significantly lower than in the control group (p=0.01)

**Figure 4**  
Meta-analysis (19) of the effect of prophylactic sclerotherapy on the incidence of variceal bleeding. The trials are arranged according to the baseline bleeding-risk, expressed as the odds after logarithmic transformation for the control groups.

**Figure 5**  
Meta-analysis (19) of the effect of prophylactic sclerotherapy on the incidence of variceal bleeding. Relationship between Odds ratio for bleeding and the baseline bleeding risk.
Table 1 - Patient characteristics at entry

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Sclerotherapy n=84</th>
<th>Controls n=82</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>56(23-76)</td>
<td>55(20-72)</td>
</tr>
<tr>
<td>Sex (M/F) (n)</td>
<td>46/38</td>
<td>49/33</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcoholic liver disease</td>
<td>41</td>
<td>40</td>
</tr>
<tr>
<td>Hepatitis B/C</td>
<td>24</td>
<td>21</td>
</tr>
<tr>
<td>PBC/PSC</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>Other</td>
<td>24</td>
<td>31</td>
</tr>
<tr>
<td>Child-Pugh class A/B/C</td>
<td>52/39/9</td>
<td>57/31/12</td>
</tr>
<tr>
<td>Child-Pugh score</td>
<td>6(5-12)</td>
<td>6(5-13)</td>
</tr>
<tr>
<td>Esophageal varices</td>
<td></td>
<td></td>
</tr>
<tr>
<td>grade II</td>
<td>47</td>
<td>42</td>
</tr>
<tr>
<td>grade III</td>
<td>38</td>
<td>40</td>
</tr>
<tr>
<td>grade IV</td>
<td>15</td>
<td>18</td>
</tr>
<tr>
<td>Ascites</td>
<td>44</td>
<td>37</td>
</tr>
<tr>
<td>Laboratory</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilirubin (µmol/l)</td>
<td>27(7-429)</td>
<td>27(7-217)</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>36(18-48)</td>
<td>35(23-47)</td>
</tr>
<tr>
<td>AT-III (IE/l)</td>
<td>0.7(0.22-1.45)</td>
<td>0.7(0.24-1.32)</td>
</tr>
<tr>
<td>ASAT (U/l)</td>
<td>44.5(12-264)</td>
<td>49(12-373)</td>
</tr>
</tbody>
</table>

Results are expressed as percentages and medians with ranges, unless otherwise indicated. Normal ranges: serum bilirubin <18 µmol/l; albumin > 37 g/l; AT-III 0.85 – 1.50 IE/l; ASAT <35 U/l
## Table 2 - Variceal bleeding

<table>
<thead>
<tr>
<th></th>
<th>Sclerotherapy</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 84</td>
<td>n = 82</td>
</tr>
<tr>
<td>Patients (n)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Variceal bleeding</td>
<td>21 (25%)</td>
<td>23 (28%)</td>
</tr>
<tr>
<td>Non-variceal bleeding</td>
<td>7  (8%)</td>
<td>7  (8.5%)</td>
</tr>
<tr>
<td>Episodes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Variceal bleeding</td>
<td>32</td>
<td>39</td>
</tr>
<tr>
<td>All upper GI-bleeding</td>
<td>48</td>
<td>49</td>
</tr>
<tr>
<td>Cause</td>
<td>Sclerotherapy</td>
<td>Controls</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>---------------</td>
<td>----------</td>
</tr>
<tr>
<td>Variceal bleeding</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td>Liver failure</td>
<td>9</td>
<td>13</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Other causes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malignancy</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Stroke</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Bleeding from duodenal ulcer</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Esophageal perforation&lt;sup&gt;1&lt;/sup&gt;</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Other causes/unknown</td>
<td>6</td>
<td>1</td>
</tr>
</tbody>
</table>

<sup>1</sup> complication of sclerotherapy

Values are number of patients
Table 4 – Complications of sclerotherapy

<table>
<thead>
<tr>
<th></th>
<th>Sclerotherapy n=84</th>
<th>Controls n=82</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Esophagus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleeding from ulceration</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Submucosal esophageal hematoma</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Stenosis</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Perforation</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Food impaction</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Dysphagia</td>
<td></td>
<td>1</td>
</tr>
<tr>
<td><strong>Infections</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacteremia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Bacterial peritonitis</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>11</td>
<td>6</td>
</tr>
</tbody>
</table>

Values are numbers of patients
eligible patients n=166
(pre)-randomization

sclerotherapy
n = 84

control group
n = 82

did not receive
sclerotherapy
n=16

sclerotherapy
n = 68

control group
n = 81

analyzed n = 84
analyzed n=82

Figure 1
-1.76 (Gregory, 1991)
-1.66 (Planas, 1989)
-1.51 (Santangelo, 1988)
-1.42 (PROVA, 1991)
-1.31 (Fleig, 1988)
-1.06 (Andreani, 1990)
-.94 (Piai, 1988)
-.91 (v.Buuren, 1995)
-.81 (Koch, 1986)
-.71 (Strauss, 1988)
-.67 (de Franchis, 1991)
-.54 (Sauerbruch, 1988)
-.45 (Potzi, 1993)
-.29 (Triger, 1989)
.19 (Witzel, 1985)
.31 (Wördehoff, 1987)
.82 (Paquet, 1994)
.86 (Kobe, 1990)
1.06 (Paquet, 1983)
Bleeding risk in control groups (odds, log scale)

Figure 5